Please login to the form below

Not currently logged in
Email:
Password:

GSK plans to be carbon neutral by 2050

GlaxoSmithKline has published its 2010 Corporate Responsibility Report, with plans for the company to be carbon neutral by 2050

GlaxoSmithKline (GSK) has published its 2010 Corporate Responsibility Report, with plans for the company to be carbon neutral by 2050.

This would mean the company would have no net carbon emissions along its production line, with GSK able to offset its emissions by investing in 'green' projects such as renewable energy, or by purchasing 'carbon credits' – a tradable permit allowing organisations to emit a certain amount of greenhouse gases.

Interim targets were also announced by GSK, with goals to reduce the company's net carbon emissions by 10 per cent over the next four years and 25 per cent over the next nine years.

Other environmental aspects of GSK's strategy include a target to reduce the company's operational water consumption by 20 per cent by 2015, and to reduce landfill waste from operations to zero by 2020.

GSK would gain financially by saving £100m a year with reduced energy, material and distribution costs according to a company statement.

As well as its environmental plans, the report desribes GSK's charitable activities, with the company stating that related initiatives in 2010 came to £222m, including £147m of product donations.

Projects to benefit from these initiatives include a five-year plan working with the World Health Organization (WHO) to expand its donation of albendazole for children at risk of intestinal worms.

Future projects were also announced by the company, with a pledge to offer its malaria vaccine candidate RTS,S at 'a level which is affordable for African countries' if approved, with all profit to be reinvested in the development of future vaccines and products for diseases in the developing world.

"There is always more that can be done but I am pleased with the progress we are making," said Andrew Witty, CEO, GSK. "Specifically this report outlines our efforts to strengthen our commitment to the environment and continue to improve access to our medicines across the world."

28th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....

Infographics